Trial
NCT05780541
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
International Network for Strategic Initiatives in Global HIV Trials (INSIGHT); University of Copenhagen; Medical Research Council; Kirby Institute; Washington D.C. Veterans Affairs Medical Center; Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; National Heart, Lung, and Blood Institute (NHLBI); US Department of Veterans Affairs; Prevention and Early Treatment of Acute Lung Injury; Cardiothoracic Surgical Trials Network; Pfizer; University of Minnesota
Condition
COVID-19
Intervention
PF-07304814
Why stopped
The agent was withdrawn from development by the manufacturer after being placed on clinical hold by the US FDA.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-09